March 23, 2018 09:27 AM EDTUpdated 10:28 AM

Director of diversity and inclusion arrives at MassBio; Jerome Jabbour takes the helm at Matinas; Ex-Eli Lilly CFO becomes president of PBM business

Amber Tong

→ In a first, the Massachusetts Biotechnology Council has brought on Edie Stringfellow as its director of diversity and inclusion, bolstering its initiative to improve …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Director of diversity and inclusion arrives at MassBio; Jerome Jabbour takes the helm at Matinas; Ex-Eli Lilly CFO becomes president of PBM business

Amber Tong

Sign up to read this article for free.

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Vertex makes money from sickle cell therapy Casgevy

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Di­rec­tor of di­ver­si­ty and in­clu­sion ar­rives at Mass­Bio; Jerome Jab­bour takes the helm at Mati­nas; Ex-Eli Lil­ly CFO be­comes pres­i­dent of PBM busi­ness

Amber Tong

Sign up to read this article for free.

Zealand’s ‘as­pi­ra­tional’ mis­sion for its amylin drug to be first-line in obe­si­ty

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

Sanofi re­veals pos­i­tive da­ta for BTK in­hibitor from $3.7B Prin­cip­ia takeover

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Director of diversity and inclusion arrives at MassBio; Jerome Jabbour takes the helm at Matinas; Ex-Eli Lilly CFO becomes president of PBM business

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Vertex makes money from sickle cell therapy Casgevy

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks